A prospective phase I/II study to evaluate allogeneic mesenchymal stromal cells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa

To evaluate the safety of allogeneic intravenously administered MSCs in children with RDEB over a 24-month period.